A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation

This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of the participants will receive NP001 and the other half will receive placebo.

Key Eligibilities:
-Onset of ALS-related weakness less than 3 years prior to first dose of study drug.
-Forced vital capacity greater than or equal to 65% of that predicted for age and height
-No tracheotomy or use of ventilatory assistance, including Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP)

**Other protocol-defined inclusion/exclusion criteria may apply. Please click on the NCT Number (below) to learn more about the study at**
Phase II
Amyotrophic lateral sclerosis
Kimberly Goslin, M.D.
Neuraltus Pharmaceuticals
Arlena Cummings
  • Providence Portland Medical Center